title
stringlengths
1
1.19k
keywords
stringlengths
0
668
concept
stringlengths
0
909
paragraph
stringlengths
0
61.8k
PMID
stringlengths
10
11
Efficacy
DISEASE
After enrollment of 27 and 25 patients in cohort 1 and cohort 2, respectively, considering that the primary study endpoint had been met for both cohorts, (cohort 1 with 18 responders and cohort 2 with 10 responders). By intention-to-treat analysis, of the 52 patients in the original cohort (i.e., before the protocol am...
PMC10425437
Survival
LIVER METASTASIS
In cohort 1, 34 (85.0%) of 40 patients had discontinued the treatment by the cutoff date, and 6 (15.0%) patients remained on treatment (Fig. In cohort 2, 31 (97%) of the 32 patients had dropped out, and 1 (3%) was still on treatment (Fig. Exploratory subgroup analysis of the full analysis set for cohorts 1 and 2 showed...
PMC10425437
Safety
hyperplasia, thrombocytopenia, myocarditis, rash, nasopharyngeal necrosis, necrosis, hypertension, hand and foot syndrome
PATHOLOGY, HYPERPLASIA, ADVERSE EVENTS, THROMBOCYTOPENIA, MYOCARDITIS, HAND-FOOT SYNDROME, NECROSIS, EVENTS, HYPERTENSION
In the safety set, dose reductions occurred in 49 (68.1%) of 72 patients for apatinib, of whom 39 (79.6%) patients required only one level of dose reduction and 17 (34.7%) patients had two levels of dose reduction. Treatment-related adverse events led to dose interruptions of apatinib in 49 (68.1%) of 72 patients, and ...
PMC10425437
B cells and tertiary lymphatic structure found in the tumors of responders in cohort 1
tumor
TUMOR
To gain insight into the mechanisms of therapeutic responses as well as biomarkers of response and resistance, longitudinal tumor samples, including baseline (before combination therapy) and relapse, were taken in the context of therapy, and molecular and immune profiling was performed (Supplementary Fig. 
PMC10425437
Angiogenesis and blood vessel density are predictive of clinical response to camrelizumab plus apatinib in cohort 2
NASOPHARYNGEAL CARCINOMA
Given that the response rate of camrelizumab plus apatinib in cohort 2 (PD-1 inhibitor-resistant) was much lower compared with cohort 1 (PD-1 inhibitor-naive), suggesting that there is significant heterogeneity among patients in these cohorts, possibly due to variances in immune microenvironments and vascular density. ...
PMC10425437
Evolution of tumor immune contexture at relapse
SECONDARY
We interrogated the TME dynamic changes of camrelizumab plus apatinib in treated patients developing secondary treatment resistance. 11 paired samples were collected at baseline and after relapse (responder
PMC10425437
Discussion
tumor, neutropenia, fatigue, leukopenia, proteinuria, tumors, hand and foot syndrome
TUMOR, NEUTROPENIA, LEUKOPENIA, ADVERSE EVENTS, DISEASE, SOLID TUMORS, MALIGNANCIES, HYPOTHYROIDISM, TUMORS
The combination of immune checkpoint inhibitors with anti-angiogenesis drugs has previously shown synergistic efficacy in patients with several types of solid tumorsDespite of a high proportion of patients with RM-NPC can achieve a response with GP plus toripalimab or camrelizumab regimens during first-line treatmentTh...
PMC10425437
Methods
PMC10425437
Study design and participants
tumor, bleeding, cancer, Tumors, necrosis, autoimmune disease, Cancer
TUMOR, BLEEDING, LIVER METASTASES, CANCER, METASTATIC DISEASE, TUMORS, NECROSIS, ONCOLOGY, EVENTS, AUTOIMMUNE DISEASE, CANCER
This single­arm, open­label, phase 2 trial was done at a single cancer center in Guangzhou, China. The same inclusion criteria would be applied to both cohorts, but the patient selection criteria differed: cohort 1 included patients with platinum-resistant RM-NPC without received immune checkpoint inhibitors for recurr...
PMC10425437
Procedures
tumor, Tumor, Cancer
ADVERSE EVENT, TUMOR, TUMOR, ADVERSE EVENTS, ADVERSE EVENT, CANCER
Patients in cohort 1 received intravenous camrelizumab 200 mg every 3 weeks plus oral apatinib 250 mg daily, and patients in cohort 2 received apatinib monotherapy in the first two weeks to modify the immune-resistant microenvironment, and then they were administered camrelizumab plus apatinib. The doses were chosen on...
PMC10425437
Outcomes
death
DISEASE PROGRESSION, DISEASE, DISEASE
The primary endpoint was the proportion of patients achieving an objective response according to RECIST version 1.1, which included patients with measurable disease who had a complete or partial response. Secondary endpoints were progression-free survival, duration of response, proportion of disease control, and safety...
PMC10425437
Statistical analysis
We used Simon’s two-stage design. For cohort 1, the previously reported data indicated that the objective response of PD-1 monotherapy in platinum-resistant NPC was about 25%For cohort 2, although the previously reported data indicated that the response rate of apatinib monotherapy in platinum-resistant NPC was about 3...
PMC10425437
Tumor sample collection and preparation
tumor
TUMOR
Fresh tumor biopsies were retrieved from NPC patients and divided into two parts on the premise of informed consent. One part of tumor biopsies was immediately put into liquid nitrogen for rapid freezing for subsequent RNA sequencing; the other part was embedded in paraffin and sectioned for immunohistochemical stainin...
PMC10425437
RNA extraction and RNA sequence
tumor
TUMOR
Total RNA was extracted from snap-frozen tumor specimens. RNA purity was checked using the NanoPhotometer ® spectrophotometer (IMPLEN, CA, USA). RNA integrity was assessed using the RNA Nano 6000 Assay Kit of the Bioanalyzer 2100 system (Agilent Technologies, CA, USA). 1 µg RNA per sample was used as input material for...
PMC10425437
RNA-seq data processing and quality check
Raw data (raw reads) of fastq format were firstly processed through in-house perl scripts. At the same time, Q20, Q30, and GC content the clean data were calculated. All the downstream analyses were based on the clean data with high quality. Reference genome and gene model annotation files were downloaded from genome w...
PMC10425437
Gene expression quantification and normalization
featureCounts v1.5.0-p3 was used to count the reads numbers mapped to each gene. And then FPKM of each gene was calculated based on the length of the gene and reads count mapped to this gene. FPKM, expected number of Fragments Per Kilobase of transcript sequence per Millions base pairs sequenced, considers the effect o...
PMC10425437
Identification of DEGs
Differential expression analysis of two conditions/groups (two biological replicates per condition) was performed using the DESeq2 R package (1.16.1). DESeq2 provide statistical routines for determining differential expression in digital gene expression data using a model based on the negative binomial distribution. Th...
PMC10425437
Deconvolution of the cellular composition with MCP-counter
The R package software MCP-counter was applied to the normalized log
PMC10425437
Pathway enrichment analyses
The network-based pathway enrichment analysis was performed using DEGs across responder and non-responder groups in the bulk-tissue RNA-seq data. In the bulk-tissue, the differentially expressed genes that had a
PMC10425437
Immunohistochemistry and multiplex immunohistochemical staining
tumor
TUMOR, AMPLIFICATION, SECONDARY
A retrospective study was performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissues of NPC and metastatic liver, lung and lymph gland. Multiplex immunohistochemical staining was performed as follow steps, 4 μm sections from full FFPE blocks of tumor tissues were sectioned, dewaxed, and fixed with 10% neutrali...
PMC10425437
TLS quantification
tumor
TUMOR
TLSs were qualified and quantified using both H&E and CD19 + CD3+ IHC staining. Structures were identified as aggregates of lymphocytes having histological features with analogous structures to that appearing in the tumor area. For the current study, criteria used for the quantification of TLS is mean area.
PMC10425437
Reporting summary
Further information on research design is available in the 
PMC10425437
Supplementary information
Supplementary InformationPeer Review FileDescription of Additional Supplementary FilesSupplementary Data 1Supplementary Data 2Supplementary Data 3Supplementary Data 4Supplementary Data 5Supplementary Data 6Reporting Summary
PMC10425437
Supplementary information
The online version contains supplementary material available at 10.1038/s41467-023-40402-x.
PMC10425437
Acknowledgements
This study was funded by grants from the National Key Research and Development Program of China (2022YFC2505800, L.Q.T.; 2022YFC2705005, H.Q.M.), National Natural Science Foundation of China (82173287, H.Q.M. and 82073003, L.Q.T.), Guangdong Basic and Applied Basic Research Foundation (2021B1515230002, H.Q.M.). The fun...
PMC10425437
Author contributions
Conception and design: H.Q.M., L.Q.T., L.Y., and Q.Y.C. designed the study. Provision of study materials or patients: L.Y., G.D.J., X.F.L., S.Y.X., S.S.G., D.F. L., L.T.L., D.H.L., Y.F.L, S.W.D., L.G., M.S.Z., X.Y.C., S.L.L., X.S.S., X.Y.L., S.C.L., Q.Y.C., L.Q.T., and H.Q.M. Data analysis and interpretation: L.Y., G.D...
PMC10425437
Peer review
PMC10425437
Data availability
The trial protocol is available as Supplementary Note The raw sequencing data can be accessed through GSA under the accession code Source data are provided with this paper. The remaining data are available within the Article, Supplementary Information, and Source Data. 
PMC10425437
Code availability
No novel code/algorithm were used in this study. All code used in this study for different expression genes, GO and KEGG enrichment, MCP–counter, and gene set variation analysis (GSVA) is available from the corresponding author upon request.
PMC10425437
Competing interests
The authors declare no competing interests.
PMC10425437
References
PMC10425437
Methods
10,495 children admitted to 18 paediatric intensive care units (ICUs) in the United Kingdom participated in a stepped-wedge, cluster randomised controlled trial, with 1955 clinical staff trained to deliver the intervention. The intervention comprised assessment and optimisation of sedation levels, and bedside screening...
PMC10681213
Results
The intervention led to a reduced duration of IMV (adjusted median difference– 7.1 hours, 95% CI -9.6 to -5.3,
PMC10681213
Conclusions
The SANDWICH trial showed a significant, although small, reduction in duration of IMV. Findings suggest that greater direction in decision-making pathways, robust embedment of new practice in unit routine, and capitalising on the skills of Advanced Nurse Practitioners and physiotherapists would have contributed to grea...
PMC10681213
Trial registration
isrctn.org Identifier:
PMC10681213
Data Availability
Owing to the data being sensitive, the minimal dataset is available via restricted access. Data is embargoed until 1 November 2025. Thereafter, it is available via restricted access conditions. To request access after the embargo period, please contact the Research Data Management (RDM) Team at Queen’s University Belfa...
PMC10681213
Introduction
critically ill
CRITICALLY ILL
This paper reports the findings of a process evaluation conducted alongside a pragmatic clinical trial that evaluated a behaviour-change intervention designed to expedite liberation from mechanical ventilation for critically ill children in the intensive care unit (ICU). The intervention was complex including several i...
PMC10681213
The sedation and weaning in children (SANDWICH) trial
The
PMC10681213
SANDWICH and usual care.
COMFORT is the name of the tool used to assess sedation and comfort of infants and children in paediatric intensive care. A full description of the intervention using the TIDieR checklist is available [The stepped wedge trial had 22 time periods; each period duration was four weeks. All participating ICUs started in th...
PMC10681213
The SANDWICH trial schematic.
The process evaluation was conducted to aid understanding of delivery of the intervention. The Medical Research Council (MRC) guidance on process evaluations [
PMC10681213
Methods
PMC10681213
Aim and objectives
The aim of the study was to determine how the processes involved in intervention delivery affected the outcome of the trial. The objectives were to determine the fidelity, dose and reach of the intervention, and the factors and processes involved in delivery of the intervention.
PMC10681213
Design
This was a process evaluation using mixed methods. We developed a logic model for the SANDWICH intervention, based on our earlier Cochrane review [
PMC10681213
SANDWICH logic model.
Adapted from Blackwood et al., 2022 [
PMC10681213
Data collection and analysis
PMC10681213
Quantitative data collection
CRF
RECRUITMENT, CRF
Data collected to determine the fidelity, dose and reach of the intervention included:Daily adherence to conducting the intervention components (multidisciplinary ward round; COMFORT assessment; screening for readiness for a spontaneous breathing trial; undertaking an SBT when screening criteria were met)Numbers of sta...
PMC10681213
Quantitative data analysis
death
EVENT, RECRUITMENT
Adherence was measured by the proportion of each intervention component performed and captured daily; the number of staff trained; and intervention reach (admissions screened divided by IMV admissions during the trial period). Due to sequential recruitment of clusters over time, we did not measure adherence over time, ...
PMC10681213
Qualitative data collection
JJ, PIS
RECRUITMENT
A senior ethnographer (JJ), who was not involved in the clinical trial, visited participating sites to undertake face-to-face individual and focus group interviews. All clinical staff involved in delivering the intervention were eligible for interviews. Recruitment entailed an initial email from the researcher comprisi...
PMC10681213
Qualitative data analysis
Data were analysed deductively and inductively. Deductively, the four components of the intervention and associated processes were used as a ‘point of entry’ into data. Inductively, Braun and Clarke’s thematic content analysis framework [
PMC10681213
Findings
RECRUITMENT
The patient recruitment period in the clinical trial was from February 2018 to October 2019 and last patient follow up was November 2019. The recruitment period for the process evaluation was from February 2018 to March 2020.In total, 10,495 admissions to 18 paediatric ICUs were analysed. Findings for all ventilated ch...
PMC10681213
Fidelity, dose and reach of the SANDWICH intervention
Across the paediatric ICUs, the intervention reached a high proportion of patients (median 82%, IQR 77%, 89%). The median (IQR) of percentage adherence to the intervention components across the paediatric ICUs was highest for setting targets on the ward round (ventilation, 90% [QR 81, 96]; sedation, 85% [IQR 63, 89]) a...
PMC10681213
Interview participants
In total, 1,955 staff from 18 paediatric ICUs were trained in the intervention and 193 of these staff participated in end of trial interviews. They included 112 nurses (bedside, senior clinical management, and advanced nurse practitioners); 42 medical staff (medical trainees and consultant intensivists); 14 allied heal...
PMC10681213
Factors and processes involved in delivery of the intervention
Supporting quotes for the following analysis are presented in
PMC10681213
Training promotes understanding and skill set
Overall, the training was considered integral to staff understanding of the purpose and content of the intervention and the effective discharge of their respective roles and responsibilities. Training was regularly discussed as time-consuming, particularly the online component. Face-to-face training was considered more...
PMC10681213
Ease and flexibility of use
PMC10681213
Intervention acceptability
The intervention was consistently validated as technically straightforward to use and accommodate within routines of care. Although bedside nurses were aware of increased documentation, overall, they endorsed the ease and flexibility with which COMFORT scoring and SBT readiness screening could be undertaken. That the i...
PMC10681213
Stasis in the absence of explicit direction
Although the intervention’s strategic flexibility was widely endorsed, it was also discussed as inadvertently working against optimal intervention delivery. Three main issues were identified. First, the flexibility inherent in the COMFORT assessment, which was categorised into a range of scores indicating sedation ‘sta...
PMC10681213
Discussion
PMC10681213
Summary of findings
The trial met its primary outcome, achieving a significant (if small) reduction in time to successful ventilator liberation. Although the intervention reached a high proportion of patients, delivery did not always encompass all components that were deemed necessary in progression towards extubation. This may explain th...
PMC10681213
Implications of the evidence for trial theory
An extensive body of research demonstrates the benefits of staff training in promoting effective delivery of novel ICU interventions [Our theory prioritised intervention ease and flexibility of use, an approach consistent with the ICU literature showing the benefits of ready integration within unit routines [Developmen...
PMC10681213
Study strengths and limitations
We followed recommended guidance and tailored the process evaluation to the trial, the intervention and the outcomes studied [The MRC Guidance on the conduct of process evaluations recommends the use of theory as a means of testing and refinement [
PMC10681213
Implications for future research
Future research should examine sustainability of the intervention in participating sites. This may shed light on the active components that were deemed by clinicians to be the most effective.
PMC10681213
Conclusion
The SANDWICH trial showed a significant, albeit small, reduction in duration of IMV for children. The process evaluation showed that the intervention’s ease of use and flexibility facilitated its adoption. Provision of a common language, designated bedside nursing involvement, and clear pathways for clinical decision-m...
PMC10681213
Supporting information
PMC10681213
SANDWICH implementation.
(DOCX)Click here for additional data file.
PMC10681213
Standards for Reporting Qualitative Research (SRQR) checklist.
(DOCX)Click here for additional data file.
PMC10681213
Process of theme development (following Braun & Clarke, 2006).
(DOCX)Click here for additional data file.
PMC10681213
Supporting quotes.
(DOCX)Click here for additional data file.
PMC10681213
References
(DOCX)Click here for additional data file.We thank the SANDWICH ICU staff champions who organised and supported the process evaluation site visits and the staff who gave of their time to participate in the interviews. We thank Ms. Margaret McKillen for transcribing the interviews.
PMC10681213
Background
COMPLICATIONS
Numerous factors are likely to result in poor treatment adherence, which is one of the important factors contributing to increased complications and the low efficacy of hemodialysis (HD), particularly inadequate knowledge of patients. This study aimed to compare the effects of a mobile health (mHealth) app (the Di Care...
PMC10308810
Methods
HD, TG, weight gain
This single-blinded, two-stage/two-group randomized clinical trial was fulfilled in 2021-22 in Iran. Seventy HD patients were recruited, using the convenience sampling method, and were then randomized into two groups: mHealth (n = 35) and face-to-face training (n = 35). ​ The patients in both groups received the same e...
PMC10308810
Results
TG
​Prior to the intervention, the mean IDWG and the K, P, TC, TG, AL, and FER levels, were not significantly different in both groups (
PMC10308810
Conclusions
The Di Care app use and the face-to-face training could improve dietary and fluid intake adherence in patients. However, mHealth could have more effect on the laboratory parameters than face-to-face training, largely reducing the IDWG.
PMC10308810
Trial registration
This study was registered in the Iranian Registry of Clinical Trials (No. ID IRCT20171216037895N5).
PMC10308810
Keywords
PMC10308810
Background
death, ESKD, kidney disease, CRF, ESRD
KIDNEY DISEASE, CRF, CHRONIC RENAL FAILURE, ESRD, COMPLICATIONS
Chronic renal failure (CRF) has been declared the 12th leading cause of death worldwide [When CRF progresses and patients reach the end stage of kidney disease (ESKD), renal replacement therapy (RRT), including hemodialysis (HD) as the most common treatment modality [However, adequate healthcare services are rarely del...
PMC10308810
Methods
PMC10308810
Design
This study was part of a single-blind, two-stage/two-group randomized clinical trial fulfilled in 2021-22 in one of the main HD centers in Isfahan, Iran, and registered in the Iranian Registry of Clinical Trials (No. ID IRCT20171216037895N5, Date: 28/04/2021). Before designing this study, a structural search was done a...
PMC10308810
Participants and sample size
HD
HEART FAILURE, CHRONIC DISEASES, DISORDERS
The sample size was calculated with 95% confidence interval and 80% test power, based on the standard deviation (SD) of treatment adherence to 4.9, obtained from the previous similar study [Then, considering the 10% sample loss in each group, 35 individuals were calculated. The inclusion criteria were the patients’ wil...
PMC10308810
Data collection
HD, TG, ®
To evaluate the effects of the interventions on treatment adherence among HD patients, the mean IDWG and the laboratory parameters were measured. One week before the intervention, the mean IDWG was recorded using the Seca 676 medical scale. To evaluate the reliability of the scale before recording the patients’ weight,...
PMC10308810
Intervention
TG
In the mHealth group, the patients utilized a researcher-made mobile-based app on the Android platform. This app is being registered under the Di Care trademark in the Intellectual Property Center of the Islamic Republic of Iran, whose main language was Persian. Before designing the app, patients’ needs and other simil...
PMC10308810
Data analysis
The data were analyzed using the SPSS Statistics software (ver. 16) via Kolmogorov-Smirnov test to checking normality, descriptive statistics (i.e., mean, SD, frequency, and percentage), and analytical tests (that is, independent-samples
PMC10308810
Results
PMC10308810
Secondary outcomes
​And
According to the criteria for poor treatment adherence based on the laboratory values ​​and IDWG mentioned in Table Of note, only 5.71% of the patients in the mHealth group had high serum K levels before the intervention, which reached zero after it (The serum TC level before the intervention in 54.28% of the patients ...
PMC10308810
Discussion
HD, TG
This study aimed to compare the effects of the mHealth app use and face-to-face training on the clinical and laboratory parameters of dietary and fluid intake adherence in HD patients. This study showed that the mean IDWG in 48.57% of the patients was higher than 5.7% of their dry weight. The rate of fluid intake non-a...
PMC10308810
Limitation
TG
The minimum version of the Android operating system was not considered as inclusion criteria and it caused some problems in sampling. Moreover, the performance of the app was different in a few smartphone brands, models, and versions of the operating system. Therefore, some features of the app, especially medication re...
PMC10308810
Authors’ contributions
MTK: The study conception and design, study execution, data extraction and interpretation, and preparation of the initial draft of manuscript; ZF: study conception and design, study search, data analysis and interpretation, and critical revision of the manuscript; SAS: study search, data interpretation, and critical re...
PMC10308810
Funding
This study is funded by Aja University of Medical Sciences. Funding will be allocated after the article is published (Funding ID is 1400.006).
PMC10308810
Data Availability
The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.
PMC10308810
Declarations
PMC10308810
Ethics approval and consent to participate
This study was approved by the Research Ethics Committee of Aja University of Medical Sciences, Tehran, Iran (ID: IR.AJAUMS.REC.1400.006). Written informed consent was obtained from all subjects after receiving an explanation of the study. All the ethical provisions of the Declaration of Helsinki for human samples were...
PMC10308810
Consent for publication
Not applicable.
PMC10308810
Competing interests
The authors declare that they have no competing interests.
PMC10308810
Abbreviations
kidney diseaserenal
RENAL DISEASE
hemodialysismobile healthinterdialytic weight gainpotassiumphosphorustotal cholesteroltriglyceridealbuminferritinchronic renal failureglomerular filtration rateend stage of kidney diseaserenal replacement therapyshort message servicetelephone follow-upIranian Registry of Clinical Trialsstandard deviationend stage renal...
PMC10308810
References
PMC10308810
1. Introduction
trunk muscle fatigue, LBP, thoracolumbar, fatigue, pain, muscle fatigue, Deep trunk muscles
CONTRACTION, CREST
Natural rubber is considered an economic plant in Thailand and is used to manufacture many products. Foam back pillows have proven to have various benefits for the lower back. However, no study has compared the effects of foam and rubber pillows. Therefore, the current study aimed to compare the efficacy of foam and ru...
PMC9964691
2. Materials and Methods
PMC9964691
2.1. Ethics Statement
Pain
This randomized crossover study was conducted at the Research Center in the Back, Neck, Other Joint Pain, and Human Performance (BNOJPH) laboratory at Khon Kaen University. The Khon Kaen University Ethics Committee (HE 632261, Khon Kaen, Thailand, 17 December 2020) approved the current study.
PMC9964691
2.2. Study Population Recruitment
low LBP
Between January 2021 and April 2021, 30 healthy participants were recruited via social media advertisements. The inclusion criteria were as follows: (i) without low LBP for at least the previous six months [
PMC9964691
2.3. Procedure
trunk muscle fatigue
A screening process was used to determine participants’ eligibility for the study, and demographic data were recorded through direct interviews. Thirty healthy participants were asked to sign informed consent forms before participating. Participants who met the inclusion criteria were then asked to visit the research l...
PMC9964691